Health
New tool can provide non-invasive decision support for NSCLC treatment – News-Medical.net
Personalized treatment options for patients with lung cancer have come a long way in the past two decades.
Reviewed by Emily Henderson, B.Sc.Oct 16 2020
Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related death worldwide, two major treatment strategies have emerged: tyrosine kinase inhibitors and immune checkpoint inhibitors. However, choosing the right therapy for a non-small cell lung cancer patient isn’t always an easy …
-
Business16 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News13 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business17 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business13 hours ago1 ASX dividend stock down 43% I’d buy right now